Aadi Bioscience to Present at Upcoming Investor Conferences
Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically defined cancers, will present at three major conferences in November 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically defined cancers, will present at three major conferences in November 2022. These include the H.C. Wainwright Precision Oncology Virtual Conference on November 14, the Jefferies London Healthcare Conference from November 15-17, and the Piper Sandler Healthcare Conference from November 29 to December 1. CEO Neil Desai and COO Brendan Delaney will engage in discussions highlighting the company's advancements, including the FDA-approved FYARRO® treatment for certain cancer patients.
Details
News Market Reaction – AADI
The recorded move for AADI in the trading session of this news was +0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences during November:
- H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference, November 14, 2022
- Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, will participate in a fireside chat with the banking equity analyst, available on demand to registered conference attendees
- Jefferies London Healthcare Conference, November 15-17, 2022, in London
- Neil Desai, Ph.D., Aadi Bioscience Founder and CEO, and Brendan Delaney, Aadi Bioscience COO, will take part in a hybrid presentation including a moderated Q&A session on Tuesday, November 15th, at 3:35 am ET (8:35 am GMT)
- Piper Sandler 34th Annual Healthcare Conference, November 29-December 1, 2022, in New York
- Dr. Desai and Mr. Delaney will participate in a fireside chat with the equity analyst on Wednesday, November 30, 2022 at 12:30 pm ET
Replays of webcasts will be available on IR pages of the Aadi Biosciences website for approximately 30 days following each presentation.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November of 2021 and in February of 2022 commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
Marcy Graham
IR@aadibio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-at-upcoming-investor-conferences-301667554.html
SOURCE Aadi Bioscience
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.